PDCD1 and neoplasm: ICIs intent to reverse this blockade of the T-cells by either binding to CTLA-4 (Ipilimumab), PD-1 (Pembrolizumab, Nivolumab) or PD-L1 (Avelumab), unblocking an anti-tumour response against MCC.